Clinical Trial Update: Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

View source ↗

Summary

An update on a clinical trial investigating urinary transglutaminase 2 as a biomarker for kidney allograft fibrosis. The study involves kidney allograft fibrosi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Allograft Fibrosis
• Kidney Transplant Failure and Rejection

Snippet

Sponsor: Asan Medical Center | Conditions: Kidney Allograft Fibrosis, Kidney Transplant Failure and Rejection | Status: UNKNOWN